CEO Steve La Neve was paid $5,114,466 in fiscal year 2026, the 29th percentile of its disclosed peer group (SEC filing 0001140361-26-039918 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,114,466 Steve La Neve total, FY2026 | 29th CEO pay percentile vs peers | — CEO-to-median pay ratio | 87.31% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
ARAY's next annual pay disclosure, estimated October 31, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steve La Neve | $525,000 | $262,500 | $4,263,749 | $0 | $0 | $0 | $63,217 | $5,114,466 |
| President and Chief Executive Officer | ||||||||
| Suzanne Winter | 314,423 | 0 | 0 | 0 | 0 | 0 | 800,000 | 1,114,423 |
| Former President and Chief Executive Officer | ||||||||
| Sandeep Chalke | 346,015 | 0 | 118,800 | 0 | 0 | 0 | 464,903 | 929,718 |
| Former Senior Vice President, Chief Commercial Officer | ||||||||
| Paul Miele | 110,885 | 87,000 | 491,920 | 0 | 0 | 0 | 4,250 | 694,055 |
| Senior Vice President, Chief Commercial Officer | ||||||||
| Ali Pervaiz | 452,333 | 0 | 131,256 | 0 | 0 | 0 | 5,437 | 589,026 |
| Senior Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Steve La Neve | $5,114,466 | — | — | — |
| Suzanne Winter | 1,114,423 | 3,042,119 | 3,516,039 | ↓ −1,927,696 |
| Sandeep Chalke | 929,718 | 1,199,334 | 1,292,908 | ↓ −269,616 |
| Paul Miele | 694,055 | — | — | — |
| Ali Pervaiz | 589,026 | 1,097,913 | 1,176,781 | ↓ −508,887 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read ACCURAY INC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ARAY reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the ACCURAY INC Peer Teardown Report
$5,114,466 Steve La Neve total, FY2026
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 16, 2026 · Source: 0001140361-26-039918 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for ARAY
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order ARAY
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name ARAY as a peer is temporarily unavailable — recheck shortly.
Get the ACCURAY INC Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2026 total |
|---|---|---|
| Ali Pervaiz | CFO | $589,026 |
| Jesse Chew | General Counsel | $1,368,412 |
| Sandeep Chalke | CCO | $929,718 |
| Suzanne Winter | CEO | $1,114,423 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2026 total |
|---|---|---|
| Anne B. Le Grand | Independent Director | $257,374 |
| Beverly A. Huss | Independent Director | $136,444 |
| Byron C. Scott | Independent Director | $109,881 |
| Chan W. Galbato | Independent Director | $140,328 |
| James M. Hindman | Independent Director | $149,881 |
| Joseph E. Whitters | Chair of the Board | $188,631 |
| Mika Nishimura | Independent Director | $124,610 |
| Robert C. Kill | Independent Director | $37,174 |
| Steven F. Mayer | Independent Director | $2,881,008 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ali Pervaiz | RSU | 88,050 | — | $22,893 |
| Ali Pervaiz | RSU | 90,000 | — | 23,400 |
| Paul Miele | RSU | 650,000 | — | 169,000 |
| Ali Pervaiz | RSU | 44,025 | — | 11,447 |
| Steve La Neve | RSU | 1,250,000 | — | 325,000 |
| Paul Miele | PSU | 747,500 | — | 194,350 |
| Steve La Neve | PSU | 1,250,000 | — | 325,000 |
| Steve La Neve | RSU | 1,064,814 | — | 276,852 |
| Ali Pervaiz | PSU | 103,500 | — | 26,910 |
| Ali Pervaiz | PSU | 79,245 | — | 20,604 |
| Ali Pervaiz | PSU | 19,811 | — | 5,151 |
The compensation philosophy emphasizes variable pay tied to specific, pre-established performance objectives or stock price appreciation over fixed pay, aiming to align executive interests with stockholders through long-term equity incentives. It seeks to attract, retain, and motivate talented executives while balancing short-term cash incentives with a heavier emphasis on long-term equity compensation to focus on long-term strategic and financial goals.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Exequity LLP |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-11-13 | 54,546,461 | 7,751,730 | 173,097 | 87.31% | Passed |
| 2024 | 2024-11-21 | 50,868,587 | 3,697,761 | 327,288 | 92.67% | Passed |
| 2023 | 2023-11-09 | 52,932,764 | 1,806,228 | 139,804 | 96.45% | Passed |
| 2022 | 2022-11-10 | 41,753,917 | 5,251,292 | 236,916 | 88.38% | Passed |
| 2021 | 2021-11-24 | 51,426,021 | 2,306,013 | 168,031 | 95.41% | Passed |
| 2020 | 2020-11-20 | 51,120,254 | 5,219,986 | 92,970 | 90.59% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-11-13 | 87.31%a |
| 2024 | 2024-11-21 | 92.67%b |
| 2023 | 2023-11-09 | 96.45%c |
a. Approved under the standard stated in the filing — “For purposes of this proposal, abstentions will have the same effect as a vote AGAINST the proposal.”.
b. Approved under the standard stated in the filing — “For purposes of this proposal, abstentions will have the same effect as a vote AGAINST the proposal.”.
c. Approved under the standard stated in the filing — “For purposes of this proposal, abstentions will have the same effect as a vote AGAINST the proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Steven F. MayerIndependent · Compensation | $47,852 | $2,473,152 | — | — | $360,004 | $2,881,008 |
| Anne B. Le GrandIndependent · Departed during FY | 76,243 | 181,131 | — | — | 0 | 257,374 |
| Joseph E. WhittersIndependent · Board Chair · Audit · Nominating and Corporate Governance (Chair) | 127,500 | 61,131 | — | — | 0 | 188,631 |
| James M. HindmanIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance | 88,750 | 61,131 | — | — | 0 | 149,881 |
| Chan W. GalbatoIndependent · Audit · Nominating and Corporate Governance | 25,197 | 115,131 | — | — | 0 | 140,328 |
| Beverly A. HussIndependent · Departed during FY | 75,313 | 61,131 | — | — | 0 | 136,444 |
| Mika NishimuraIndependent · Compensation (Chair) · Audit · Nominating and Corporate Governance | 63,478 | 61,131 | — | — | 0 | 124,610 |
| Byron C. ScottIndependent · Departed during FY | 48,750 | 61,131 | — | — | 0 | 109,881 |
| Robert C. KillIndependent | 37,174 | 0 | — | — | 0 | 37,174 |
| Steve La NeveEmployee director · Partial-year service | — | — | — | — | — | 0 |
| Richard A. MeierIndependent · Compensation · Partial-year service · Newly elected | 0 | 0 | — | — | 0 | 0 |
| Annual cash retainer | $52,500 |
|---|---|
| Annual equity retainer | $150,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 15,000 / 10,000 |
| Stock ownership guideline | $4 |
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $590,257 |
| Equity awards (grant-date value) | $3,075,069 |
| All other compensation | $360,004 |
| Total cost of the board | $4,025,330 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies ACCURAY INC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including ACCURAY INC.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Merit Medical Systems, Inc. | 2025 | Fred Lampropoulos | $1,890,000 | $9,313,606 | $0 | $1,882,894 | $13,755,143 |
| 2 | RadNet, Inc. | 2025 | Howard Berger | 3,000,000 | 8,999,966 | 0 | 0 | 12,087,934 |
| 3 | Glaukos Corporation | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 4 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 5 | iRhythm Technologies, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 6 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 7 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 8 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 9 | Inspire Medical Systems, Inc. | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 10 | CONMED Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 11 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 12 | Cutera, Inc. | 2023 | Taylor Harris | 271,023 | 2,747,682 | 4,250,008 | 0 | 7,279,813 |
| 13 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 14 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 15 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 16 | ACCURAY INC | 2026 | Steve La Neve | 525,000 | 4,263,749 | 0 | 0 | 5,114,466 |
| 17 | Inari Medical, Inc. | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 18 | Varex Imaging Corporation | 2025 | Sunny Sanyal | 815,816 | 2,662,978 | 0 | 1,131,894 | 4,634,688 |
| 19 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 20 | Inogen, Inc. | 2025 | Kevin R.M. Smith | 711,077 | 1,874,550 | 0 | 0 | 2,613,804 |
| 21 | Lantheus Holdings, Inc. | 2025 | Mary Anne Heino | 100,000 | 749,963 | 749,999 | 0 | 2,173,930 |
| 22 | Penumbra, Inc. | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| ACCURAY INC | 0% | PSU 50 · RSU 50 | No | Exequity LLP |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | 141% | PSU 70 · RSU 30 | No | Korn Ferry |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| CONMED Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Cutera, Inc. | not disclosed | not disclosed | No | Compensia |
| Glaukos Corporation | 177.5% | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Inari Medical, Inc. | 118% | RSU 75 · Option 25 | not disclosed | FW Cook |
| Inogen, Inc. | 60% | RSU 50 · PRSU 50 | No | Aon |
| Inspire Medical Systems, Inc. | 111.4% | PSU 50 · RSU 50 | No | Aon |
| iRhythm Technologies, Inc. | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| Lantheus Holdings, Inc. | 47% | PSU 50 · RSU 25 · Options 25 | Yes — relative Total Shareholder Return (rTSR) against the S&P 400 Health Care Index | Pearl Meyer |
| Merit Medical Systems, Inc. | 124.53% | PSU 60 · RSU 40 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Penumbra, Inc. | not disclosed | not disclosed | No | Compensia |
| RadNet, Inc. | not disclosed | RSU 100 | No | Pearl Meyer |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| Varex Imaging Corporation | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR | FW Cook |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Steve La Neve | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Fiscal 2026 Summary Compensation Table” · page 42. As printed: 5,114,466. Filing ↗machine: r2 · c24 · span 597587–597596 |
| 2 | Section 01, Suzanne Winter | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Fiscal 2026 Summary Compensation Table” · page 42. As printed: 1,114,423. Filing ↗machine: r6 · c24 · span 615978–615987 |
| 3 | Section 01, Sandeep Chalke | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Fiscal 2026 Summary Compensation Table” · page 42. As printed: 929,718. Filing ↗machine: r8 · c24 · span 625100–625107 |
| 4 | Section 01, Paul Miele | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Fiscal 2026 Summary Compensation Table” · page 42. As printed: 694,055. Filing ↗machine: r5 · c24 · span 611335–611342 |
| 5 | Section 01, Ali Pervaiz | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Fiscal 2026 Summary Compensation Table” · page 42. As printed: 589,026. Filing ↗machine: r3 · c24 · span 602271–602278 |
| 6 | Section 07, pay ratio | 10-K | 2026-08-27 | 0001437749-26-029098 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 7 | Section 08, Steven F. Mayer | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 2,881,008. Filing ↗machine: span 957980–958164 |
| 8 | Section 08, Anne B. Le Grand | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 257,374. Filing ↗machine: span 955691–955915 |
| 9 | Section 08, Joseph E. Whitters | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 188,631. Filing ↗machine: span 968062–968286 |
| 10 | Section 08, James M. Hindman | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 149,881. Filing ↗machine: span 950595–950819 |
| 11 | Section 08, Chan W. Galbato | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 140,328. Filing ↗machine: span 970786–971010 |
| 12 | Section 08, Beverly A. Huss | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 136,444. Filing ↗machine: span 952967–953191 |
| 13 | Section 08, Mika Nishimura | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 124,610. Filing ↗machine: span 963018–963242 |
| 14 | Section 08, Byron C. Scott | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 109,881. Filing ↗machine: span 965740–965964 |
| 15 | Section 08, Robert C. Kill | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 37,174. Filing ↗machine: span 960661–960885 |
| 16 | Section 08, Steve La Neve | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 08, Richard A. Meier | DEF 14A | 2026-10-16 | 0001140361-26-039918 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 06, 2025 vote | Form 8-K | 2025-11-19 | 0001193125-25-288077 | Item 5.07 · say-on-pay result. As reported: 87.31% (votes for as printed: 54,546,461). Filing ↗ |
| 19 | Section 06, 2024 vote | Form 8-K | 2024-11-25 | 0000950170-24-130548 | Item 5.07 · say-on-pay result. As reported: 92.67% (votes for as printed: 50,868,587). Filing ↗ |
| 20 | Section 06, 2023 vote | Form 8-K | 2023-11-15 | 0000950170-23-064162 | Item 5.07 · say-on-pay result. As reported: 96.45% (votes for as printed: 52,932,764). Filing ↗ |
| 21 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 22 | Section 09b board cost (computed) | Computed | — | — | Cash 590,257 + equity 3,075,069 + all other 360,004 = 4,025,330, summed across the director compensation table rows.machine: formula: Σ = 4,025,330 |
| 23 | Merit Medical Systems, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0000856982-26-000013 | CEO total compensation as printed in Merit Medical Systems, Inc.'s own proxy. As printed: 13,755,143. Filing ↗machine: r21 · c8 · span 1277869–1277879 |
| 24 | RadNet, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001683168-26-003086 | CEO total compensation as printed in RadNet, Inc.'s own proxy. As printed: 12,087,934. Filing ↗machine: t93 · r1 · c26 · span 428610–428620 |
| 25 | Glaukos Corporation, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-157829 | CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952 |
| 26 | Nevro Corp., Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044100 | CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993 |
| 27 | iRhythm Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 28 | Alphatec Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191867 | CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158 |
| 29 | Avanos Medical, Inc., Section 10b CEO total | DEF 14A | 2026-03-12 | 0001104659-26-027106 | CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. Filing ↗machine: r1 · c53 · span 1674377–1674386 |
| 30 | AtriCure, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 31 | Inspire Medical Systems, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001140361-26-010490 | CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877 |
| 32 | CONMED Corporation, Section 10b CEO total | DEF 14A | 2026-04-07 | 0000816956-26-000047 | CEO total compensation as printed in CONMED Corporation's own proxy. As printed: 7,634,873. Filing ↗machine: r3 · c27 · span 1186564–1186573 |
| 33 | Orthofix Medical Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191716 | CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. Filing ↗machine: t96 · r4 · c16 · span 1472329–1472338 |
| 34 | Cutera, Inc., Section 10b CEO total | DEF 14A | 2024-06-17 | 0001628280-24-028528 | CEO total compensation as printed in Cutera, Inc.'s own proxy. As printed: 7,279,813. Filing ↗machine: r4 · c46 · span 1221355–1221364 |
| 35 | Artivion, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001999371-26-007510 | CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882 |
| 36 | Tandem Diabetes Care, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001438133-26-000034 | CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972 |
| 37 | AngioDynamics, Inc., Section 10b CEO total | DEF 14A | 2026-10-08 | 0001140361-26-039022 | CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. Filing ↗machine: r2 · c27 · span 739870–739879 |
| 38 | ACCURAY INC (subject), Section 10b CEO total | DEF 14A | 2026-10-16 | 0001140361-26-039918 | CEO total compensation as printed in ACCURAY INC's own proxy. As printed: 5,114,466. Filing ↗machine: r2 · c24 · span 597587–597596 |
| 39 | Inari Medical, Inc., Section 10b CEO total | DEF 14A | 2024-03-13 | 0001193125-24-066805 | CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517 |
| 40 | Varex Imaging Corporation, Section 10b CEO total | DEF 14A | 2025-12-29 | 0001104659-25-124842 | CEO total compensation as printed in Varex Imaging Corporation's own proxy. As printed: 4,634,688. Filing ↗machine: r1 · c53 · span 911140–911149 |
| 41 | Tactile Systems Technology, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001104659-26-034206 | CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. Filing ↗machine: r3 · c12 · span 865797–865806 |
| 42 | Inogen, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001294133-26-000009 | CEO total compensation as printed in Inogen, Inc.'s own proxy. As printed: 2,613,804. Filing ↗machine: span 1140571–1140580 |
| 43 | Lantheus Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001193125-26-117649 | CEO total compensation as printed in Lantheus Holdings, Inc.'s own proxy. As printed: 2,173,930. Filing ↗machine: r3 · c39 · span 957618–957628 |
| 44 | Penumbra, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001321732-26-000010 | CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. Filing ↗machine: span 424797–424804 |
| 45 | Section 10a, Alphatec Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-191867 | Alphatec Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 46 | Section 10a, AngioDynamics, Inc. reciprocity | DEF 14A | — | 0001140361-26-039022 | AngioDynamics, Inc. names ACCURAY INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 47 | Section 10a, Glaukos Corporation reciprocity | DEF 14A | — | 0001193125-26-157829 | Glaukos Corporation's most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 48 | Section 10a, RadNet, Inc. reciprocity | DEF 14A | — | 0001683168-26-003086 | RadNet, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 49 | Section 10a, Tactile Systems Technology, Inc. reciprocity | DEF 14A | — | 0001104659-26-034206 | Tactile Systems Technology, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 50 | Section 10a, Varex Imaging Corporation reciprocity | DEF 14A | — | 0001104659-25-124842 | Varex Imaging Corporation names ACCURAY INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 51 | Section 10a, iRhythm Technologies, Inc. reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 52 | Section 10a, Inspire Medical Systems, Inc. reciprocity | DEF 14A | — | 0001140361-26-010490 | Inspire Medical Systems, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 53 | Section 10a, Avanos Medical, Inc. reciprocity | DEF 14A | — | 0001104659-26-027106 | Avanos Medical, Inc. names ACCURAY INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 54 | Section 10a, Artivion, Inc. reciprocity | DEF 14A | — | 0001999371-26-007510 | Artivion, Inc. names ACCURAY INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 55 | Section 10a, AtriCure, Inc. reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 56 | Section 10a, CONMED Corporation reciprocity | DEF 14A | — | 0000816956-26-000047 | CONMED Corporation's most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 57 | Section 10a, Merit Medical Systems, Inc. reciprocity | DEF 14A | — | 0000856982-26-000013 | Merit Medical Systems, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 58 | Section 10a, Penumbra, Inc. reciprocity | DEF 14A | — | 0001321732-26-000010 | Penumbra, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 59 | Section 10a, Cutera, Inc. reciprocity | DEF 14A | — | 0001628280-24-028528 | Cutera, Inc. names ACCURAY INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 60 | Section 10a, Tandem Diabetes Care, Inc. reciprocity | DEF 14A | — | 0001438133-26-000034 | Tandem Diabetes Care, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 61 | Section 10a, Inari Medical, Inc. reciprocity | DEF 14A | — | 0001193125-24-066805 | Inari Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 62 | Section 10a, Orthofix Medical Inc. reciprocity | DEF 14A | — | 0001193125-26-191716 | Orthofix Medical Inc. names ACCURAY INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 63 | Section 10a, Nevro Corp. reciprocity | DEF 14A | — | 0000950170-24-044100 | Nevro Corp.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
| 64 | Section 10a, Inogen, Inc. reciprocity | DEF 14A | — | 0001294133-26-000009 | Inogen, Inc.'s most recent proxy was read; its disclosed peer group does not include ACCURAY INC. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the ACCURAY INC Executive Compensation Report
$1,500